Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$94.39M-28.9%-$58.58M+1.4%-$114.19M-6.8%-$42.28M+72.2%-$73.24M+50.4%
$386K+1.8%$392K+8.0%$358K+20.1%$377K+41.2%$379K+126%
$34.02M+62.5%$25.79M+45.9%$26.25M+46.7%$25.16M+3.1%$20.93M+5.2%
-$167.44M-88.4%-$133.46M-27.7%-$47.05M+65.1%-$88.89M+40.4%
$3.85M$857K+10.0%$0-100%$0-100%
$192.19M+17.3%$27.58M+158%$47.86M+139%$163.88M+67.1%
$2.33M-73.0%$8.96M-54.7%$236.65M+3,071%$1.74M-98.7%$8.64M-98.5%
$28.41M-66.0%$109.5M$2.55M$83.63M-84.0%
-$171.28M-92.7%-$133.07M-27.1%-$47.05M+65.2%-$88.89M+40.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Madrigal Pharmaceuticals, Inc. generate?
Madrigal Pharmaceuticals, Inc. (MDGL) generated -$436.8M in operating cash flow over the trailing twelve months.
What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
After $4.7M of capital expenditures, Madrigal Pharmaceuticals, Inc.'s free cash flow was -$440.3M over the trailing twelve months, up 3.7% year over year.
Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.